MAP3K20 and neoplasm: These results, in combination with the up-regulation (after priming treatment) of ZAK (also known as MLK7), encoding a MAP3 kinase that has been shown to activate JNK [50], may explain the differences in tumor regrowth between groups receiving priming and single administration.